Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…
NEW YORK (Reuters Health) – Lung cancer patients undergoing chemotherapy can be treated safely with erythropoiesis-stimulating agents (ESAs), according to findings published in the 24 January online issue…
NEW YORK (Reuters Health) – Avanafil, another phosphodiesterase type 5 (PDE5) inhibitor, improves sexual function in men with erectile dysfunction, according to a report in the January 16th…
NEW YORK (Reuters Health) – A review suggests that wound-edge protection devices (WEPDs) may be useful in surgical patients, UK researchers report in a January 26th on-line paper…
NEW YORK (Reuters Health) – Birth defects are uncommon in offspring of women exposed to leflunomide before conception or in the first trimester of pregnancy, according to a…
NEW YORK (Reuters Health) – Men 60 years old and younger have excellent quality-of-life outcomes after proton therapy for prostate cancer, according to findings published in the January…
NEW YORK (Reuters Health) – Cabergoline in combination with low-dose pegvisomant is effective in treating patients with active acromegaly, researchers from UK report in the January 25th online…
NEW YORK (Reuters Health) – Stereotactic body radiotherapy (SBRT) may be an effective alternative to surgery for solitary pulmonary nodules clinically diagnosed as lung cancer, researchers from Japan…
NEW YORK (Reuters Health) – There is no need to avoid proton pump inhibitors (PPIs) in patients on the platelet inhibitors clopidogrel or ticagrelor. The increased rates of…
Robert Klitzman, MD, Professor of Clinical Psychiatry at the Columbia University Medical Center, discusses the advantages and disadvantages of full genome sequencing. With new advances and breakthroughs in…
NEW YORK (Reuters Health) – Data from the German drug-eluting stent (DES.DE) Registry provide no evidence of the “obesity paradox” in the setting of percutaneous coronary intervention (PCI)…
